Wegovy for Adults 65 and Older: What the Geriatric Transition to Adult Care Means for You

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

Does the Wegovy label set an upper age limit?

Wegovy injection is indicated, with a reduced-calorie diet and more physical activity, to reduce excess body weight and maintain weight reduction long term in adults and in children aged 12 and older with obesity, and in adults with overweight plus at least one weight-related condition. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and to treat noncirrhotic MASH with moderate to advanced fibrosis in adults [1]. The indication statements say 'adults' and name no upper age cutoff [1]. The Wegovy tablets are indicated for adults only and carry no pediatric or MASH indication [1].

Contraindications are the same at any age: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, or a prior serious hypersensitivity reaction to semaglutide or an excipient [1].

Dose schedule

The Wegovy injection is approved from age 12, and the dose ceilings differ by age group: adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go to a maximum of 7.2 mg weekly, while the pediatric maximum is 2.4 mg [1]. The tablets have no pediatric indication [1].

The label titration is 0.25 mg weekly for 4 weeks, 0.5 mg for 4 weeks, 1 mg for 4 weeks, 1.7 mg for 4 weeks, then maintenance, with 2.4 mg the recommended dose for weight reduction and 1.7 mg also a maintenance option [1]. A missed dose may be given if the next scheduled dose is more than 2 days away, and after two or more consecutive missed doses the label says to re-escalate starting from a lower dose [1].

A tablet version also exists for adults. Wegovy 25 mg tablets are taken once daily on an empty stomach in the morning with up to 4 ounces of plain water, swallowed whole, with at least 30 minutes before food, drink or other oral medicines; a missed dose is skipped [1].

What the trials show

STEP 1 randomized 1,961 adults with a BMI of at least 30, or at least 27 with a weight-related condition, and no diabetes, to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was -14.9% versus -2.4%, and 86.4% versus 31.5% lost at least 5% of body weight [4]. In the pooled Wegovy weight-management safety trials, 42% of participants had hypertension and 4% had cardiovascular disease [1].

SELECT is the trial that matches an older adult with heart disease most closely. It enrolled 17,604 adults aged 45 and older with established cardiovascular disease and a BMI of at least 27, none with diabetes, and followed them for a mean 39.8 months [2]. The three-part endpoint of cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.5% on semaglutide 2.4 mg and 8.0% on placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90) [2]. On the label's table, cardiovascular death on its own was 2.5% versus 3.0% (hazard ratio 0.85, 0.71 to 1.01) and superiority was not confirmed for that component in the testing hierarchy; all-cause death was 4.3% versus 5.2% and fatal or non-fatal heart attack 2.8% versus 3.8% (hazard ratio 0.72) [1]. Mean weight change at week 104 was -9.4% versus -0.9%, and 16.6% versus 8.2% stopped treatment because of adverse events [1].

Label warnings relevant at 65

Insulin and sulfonylureas

The Wegovy label says the risk of hypoglycemia increases when Wegovy is used with insulin or an insulin secretagogue such as a sulfonylurea, and that reducing the dose of the insulin or secretagogue may be necessary when Wegovy is started [1]. In the adult weight-management trial that included people with type 2 diabetes and a BMI of at least 27, glucose below 54 mg/dL occurred in 6.2% on Wegovy 2.4 mg versus 2.5% on placebo, and the risk was higher in people taking a sulfonylurea [1]. Adding Wegovy to insulin has not been evaluated, and Wegovy has not been studied in type 1 diabetes [1].

Kidneys and fluid loss

The label warns about acute kidney injury from volume depletion and says to monitor renal function in patients reporting reactions that could lead to volume depletion [1]. In the Wegovy trials, acute kidney injury occurred at 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with prior renal impairment and during dose titration, often after gastrointestinal fluid loss [1].

Heart rate

The Wegovy label lists heart rate increase as a warning: a mean rise of 1 to 4 beats per minute, with a rise of 20 beats per minute or more in 26% of Wegovy-treated patients versus 16% on placebo, and it says to monitor heart rate at regular intervals [1]. The Ozempic label does not list this warning [3].

Gallbladder, pancreas and procedures

In the adult weight-management trials, cholelithiasis was reported by 1.6% on Wegovy injection versus 0.7% on placebo, and cholecystitis by 0.6% versus 0.2% [1]. The label says to discontinue Wegovy if pancreatitis is suspected [1]. It also warns that pulmonary aspiration has been reported during general anesthesia or deep sedation in people taking GLP-1 receptor agonists, and says to tell healthcare providers about planned surgery or procedures [1]. A Wegovy pen must never be shared between patients, even with a new needle [1].

Kidneys, liver and drug clearance

The Ozempic label recommends no dose adjustment for renal or hepatic impairment [3]. The Wegovy label's pharmacokinetic data found no clinically significant difference in semaglutide exposure across eGFR 30 to under 90 or Child-Pugh A to C hepatic impairment [1]. Semaglutide has a half-life of about a week and is broken down by cleavage of the peptide backbone and beta-oxidation of the fatty acid side chain rather than by CYP enzymes; the drug stays in the body for roughly 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection [1].

What the trials recorded

The main safety pool covers 2,116 adults on Wegovy 2.4 mg and 1,261 on placebo for up to 68 weeks. Nausea occurred in 44% versus 16%, diarrhea 30% versus 16%, vomiting 24% versus 6%, constipation 24% versus 11%, abdominal pain 20% versus 10%, headache 14% versus 10%, fatigue 11% versus 5%, dizziness 8% versus 4%, and hair loss 3% versus 1%; hypoglycemia in people with type 2 diabetes was 6% versus 2%, any gastrointestinal reaction 73% versus 47%, and 6.8% versus 3.2% stopped treatment for adverse reactions [1].

At the 7.2 mg dose, across two 72-week trials with 1,311 adults on 7.2 mg, 304 on 2.4 mg and 303 on placebo, nausea occurred in 39%, 35% and 13%; vomiting in 22%, 16% and 6%; dysesthesia (altered skin sensation such as burning or pain from touch) in 22%, 6% and 0%; and constipation in 20%, 19% and 8%. Treatment was stopped for adverse reactions in 5%, 5% and 2% [1]. The label says dysesthesia rises with dose and that 18% of those affected on 7.2 mg had not recovered by the end of the trial [1].

Fatigue, dizziness and low blood pressure

The label also documents fatigue (11% versus 5%), dizziness (8% versus 4%), and hypotension reactions (1.3% versus 0.4%) with syncope (0.8% versus 0.2%) in the Wegovy trials [1].

Stopping Wegovy

STEP 4 randomized 803 adults who had reached 2.4 mg after a 20-week run-in to continue semaglutide or switch to placebo for 48 weeks. From week 20 to week 68, the continuing group changed by -7.9% and the placebo group by +6.9%, a difference of 14.8 percentage points [5]. The STEP 1 extension included 327 participants. Those who received semaglutide had lost an average of 17.3% by week 68 and regained 11.6 percentage points in the year after stopping, for a net loss of 5.6% at week 120 versus 0.1% on placebo [6].